Comparison of effectiveness of a food supplement product versus Fosfomycin in the treatment of female recurrent urinary tract infections: Preliminary results of a multicenter comparative observational study
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction an objective: Urinary tract infections (UTIs) are a significant health concern with high costs and poor quality of life (QoL) impact. Managing recurrent UTIs (rUTI) in women requires effective treatments that relieve symptoms and reduce recurrence, while also sparing antibiotics due to rising resistance. This study evaluates the efficacy of a nutritional supplement in reducing UTI recurrences and improving QoL compared to antibiotic therapy. Materials and methods: The study compared the effectiveness of a dietary supplement (containing D-mannose, Palmitoylethanolamide, N-acetylcysteine, Lactobacillus rhamnosus, and Hibiscus extract) with a low dose of Fosfomycin in treating recurrent urinary tract infections (rUTI) in women. Both treatments were administered for 6 months, with clinical and microbiological evaluations at 3 and 6 months. Quality of life and patient satisfaction were assessed using specific questionnaires. Fosfomycin was given every 10 days, while the supplement was taken for 14 days each month. Results: The study involved 55 patients in the nutritional supplement group (NGroup) and 34 in the Fosfomycin group (FGroup). In the NGroup, the average age was 62.2 years, with a BMI of 27.2. UTIs significantly decreased from 1.87 at baseline to 0.51 at 3 months and 0.28 at 6 months ( p < 0.001). Few mild gastrointestinal side effects were reported. Quality of life (QoL) and satisfaction both improved significantly. In the FGroup, the average age was 62.9 years, with a lower BMI of 23.5. UTIs also decreased from 2.68 at baseline to 0.87 at 3 months and 0.67 at 6 months ( p < 0.001). No side effects were reported. QoL improved, but satisfaction declined significantly. Both groups showed similar improvements in UTI frequency and QoL, but the Fosfomycin group had lower satisfaction overall.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Comparison of effectiveness of a food supplement product versus Fosfomycin in the treatment of female recurrent urinary tract infections: Preliminary results of a multicenter comparative observational study
- Date Crossref
- 21/07/2026
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Pisa Unit of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
Azienda Ospedaliero-Universitaria Careggi pays non établi dans la noticeÉtablissement de santé
-
Azienda Ospedaliera Sant'Andrea pays non établi dans la noticeÉtablissement de santé
-
University of Siena Unit of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Careggi University Hospital Unit of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Sapienza University Unit of Urology pays non établi dans la noticeUniversité ou école supérieure
Unit of Obstetrics and Gynecology — University of Pisa, Azienda Ospedaliero-Universitaria Careggi et Azienda Ospedaliera Sant'Andrea, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.